Esperion Therapeutics, Inc. (ESPR)

Esperion Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	407	340	459	145	725	1,630
Market Cap Growth	307.34%	-25.93%	215.74%	-79.94%	-55.52%	32.13%
Enterprise Value	730	799	797	353	782	1,562
PE Ratio	-	-1.62	-1.96	-0.54	-5.05	-16.77
PS Ratio	1.77	2.92	6.08	1.85	3.19	10.98
PB Ratio	-1.68	-0.75	-1.42	-0.74	-7.54	81.68
P/FCF Ratio	-18.12	-2.51	-2.63	-0.55	-8.42	-22.86
P/OCF Ratio	-18.16	-2.51	-2.63	-0.55	-8.51	-23.17
EV/Sales Ratio	3.18	6.87	10.56	4.50	3.44	10.53
EV/EBITDA Ratio	-29.42	-5.32	-4.52	-1.59	-6.50	-17.60
EV/EBIT Ratio	-29.33	-5.32	-4.51	-1.59	-6.47	-17.54
EV/FCF Ratio	-29.89	-5.90	-4.56	-1.34	-9.09	-21.91
Debt / Equity Ratio	-1.87	-1.19	-1.56	-2.63	-3.77	6.72
Debt / EBITDA Ratio	-19.74	-3.60	-2.86	-2.33	-3.01	-1.51
Debt / FCF Ratio	-20.05	-3.99	-2.89	-1.96	-4.21	-1.88
Quick Ratio	1.71	0.84	2.17	4.53	3.37	3.05
Current Ratio	2.22	1.29	2.67	4.49	3.68	3.20
Asset Turnover	0.89	0.51	0.25	0.27	0.82	0.59
Interest Coverage	-0.48	-2.55	-3.11	-4.81	-5.33	-10.97
Return on Equity (ROE)	22.60%	53.40%	80.70%	95.00%	1105.70%	-98.90%
Return on Assets (ROA)	-33.40%	-91.60%	-77.40%	-92.30%	-51.50%	-38.30%
Return on Capital (ROIC)	-13.63%	-180.99%	-99.30%	-70.79%	-45.66%	-60.43%
Earnings Yield	-21.24%	-61.54%	-50.90%	-185.10%	-19.81%	-5.96%
FCF Yield	-6.72%	-39.85%	-38.08%	-181.45%	-11.87%	-4.38%
Buyback Yield / Dilution	-141.77%	-55.26%	-129.76%	-5.20%	-1.42%	-1.26%
Total Shareholder Return	-141.77%	-55.26%	-129.76%	-5.20%	-1.42%	-1.26%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).